Browse every story filed under this topic, curated from trusted publishers around the world.
FDA approves 1st 2-drug HIV treatment
The FDA has approved Merck’s once-daily, two-drug regimen for adults with virologically suppressed HIV-1. The treatment combines 100 mg doravirine and 0.25 mg islatravir and is indicated for patients with no history of virologic treatment failure …
Read full story →Merck goes with Google for AI push, striking enterprise partnership worth up to $1B
Amid industry layoffs and M&A headlines, Big Pharma's embrace of AI is gaining more steam.
Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso
The once-daily HIV treatment regimen offers a new mechanism of action in the HIV treatment market.
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect Welireg surprisingly …
STAT+: Pharmalittle: We’re reading about a Purdue Pharma settlement, a setback for Merck and Eisai, and more
A U.S. judge is expected to direct Purdue Pharma to forfeit $225 million to the Justice Department, clearing the way …
STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem
At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myeloma.
You've seen all articles for #merck.
Check back
soon
for new stories.